Specify a stock or a cryptocurrency in the search bar to get a summary
Lytix Biopharma AS
LYTIXLytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway. Address: Sandakerveien 138, Oslo, Norway, 0484
Analytics
WallStreet Target Price
176.79 NOKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures LYTIX
Dividend Analytics LYTIX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History LYTIX
Stock Valuation LYTIX
Financials LYTIX
Results | 2019 | Dynamics |